Immunic (IMUX) director Jon Congleton granted 25,370 stock options at $14.80
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
IMMUNIC, INC. director Jon Congleton received a grant of stock options covering 25,370 shares of common stock at an exercise price of $14.80 per share. The option vests in monthly installments over one year from the grant date and expires on July 5, 2036. Following this grant, Congleton holds 25,370 options directly, with no accompanying share purchases or sales reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Congleton Jon
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 25,370 | $0.00 | -- |
Holdings After Transaction:
Stock Option — 25,370 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 25,370 options
Exercise price: $14.80 per share
Underlying shares: 25,370 common shares
+2 more
5 metrics
Stock options granted
25,370 options
Grant to director Jon Congleton on July 5, 2026
Exercise price
$14.80 per share
Strike price for Congleton’s stock option award
Underlying shares
25,370 common shares
Shares subject to the option grant
Expiration date
July 5, 2036
Option term for Congleton’s grant
Total options after grant
25,370 options
Direct holdings following this transaction
Key Terms
Stock Option, grant/award acquisition, Common Stock, vests in monthly increments
4 terms
Stock Option financial
"The security reported is titled "Stock Option" linked to common stock."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
grant/award acquisition financial
"The transaction_action field notes a "grant/award acquisition"."
Common Stock financial
"The underlying security title for the option is "Common Stock"."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vests in monthly increments financial
"The option vests in monthly increments over a period of one year."
FAQ
What insider transaction did IMMUNIC (IMUX) report for Jon Congleton?
IMMUNIC reported that director Jon Congleton received a grant of 25,370 stock options. These options relate to common stock and represent equity-based compensation rather than an open-market share purchase or sale by the director.
What is the exercise price of Jon Congleton’s IMMUNIC (IMUX) stock options?
The granted stock options have an exercise price of $14.80 per share. This is the price at which Congleton may buy IMMUNIC common shares if he chooses to exercise the options in the future.
How do Jon Congleton’s IMMUNIC (IMUX) stock options vest?
The option award vests in monthly increments over one year from the grant date. This means a portion of the 25,370 options becomes exercisable each month during the first year after the grant.
When do Jon Congleton’s IMMUNIC (IMUX) stock options expire?
The stock options granted to Jon Congleton expire on July 5, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase IMMUNIC common stock.
How many IMMUNIC (IMUX) options does Jon Congleton hold after this grant?
After this transaction, Jon Congleton holds 25,370 stock options directly. This total reflects the new grant reported and does not indicate any prior option or share holdings in this specific filing.